ArticleInternational journal of cardiology. Cardiovascular risk and prevention2026
Cardiac, oxidative stress, and fibrosis-related biomarkers and new-onset heart failure: Systematic review and meta-analysis.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond statistical association: Interpreting the clinical utility of biomarkers for incident heart failure prediction.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Circulating biomarkers reflecting pathophysiological pathways, including myocardial stress, injury, oxidative stress, and fibrosis, may facilitate early identification of individuals at increased risk of heart failure (HF) in the general population. However, the strength and consistency of associations between these biomarkers and incident HF have not been comprehensively evaluated. Methods: A comprehensive search of relevant databases (inception-September 2024) identified population-based studies reporting biomarkers associated with incident HF in individuals without a prior HF history. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random effects meta-analysis. Results: Across 47 included studies, nine biomarkers were significantly associated with new-onset HF in multivariate-adjusted analyses: N-terminal pro b-type natriuretic peptide (NT-proBNP) (HR 2.03, 95% CI: 1.82-2.25, P < 0.01), high-sensitivity cardiac troponin I (hs-cTnI) (HR 1.58, 95% CI: 1.42-1.76, P < 0.01), high-sensitivity cardiac troponin T (hs-cTnT) (HR 1.74, 95% CI: 1.36-2.22, P < 0.01), midregional pro-atrial natriuretic peptide (MR-proANP) (HR 1.54, 95% CI: 1.39-1.71, P < 0.01), b-type natriuretic peptide (BNP) (HR 1.57, 95% CI: 1.44-1.71, P < 0.01), growth differentiation factor 15 (GDF-15) (HR 1.51, 95% CI: 1.36-1.68, P < 0.01), midregional proadrenomedullin (MR-proADM) (HR 1.38, 95% CI: 1.10-1.74, P < 0.01), fibroblast growth factor 23 (FGF-23) (HR 1.17, 95% CI: 1.10-1.25, P < 0.01), and galectin-3 (Gal-3) (HR 1.23, 95% CI: 1.12-1.35, P < 0.01). HF phenotypes and sex differences were also evaluated. Conclusions: Higher levels of NT-proBNP, hs-cTnI, hs-cTnT, MR-proANP, BNP, GDF-15, MR-proADM, FGF-23, and Gal-3 were associated with a larger risk of incident HF, supporting their utility as biomarkers for predicting HF development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.